1. Introduction {#sec1}
===============

Clinical trials of human medicines for marketing authorization applications in Japan must comply with the ministerial ordinance on GCP. This requirement was based on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guidelines E6 (Guideline for Good Clinical Practice) enacted in April 1998 \[[@bib1]\].

In Japan, the Pharmaceuticals and Medical Devices Agency (PMDA) conducts GCP inspections during submission of new drug applications (NDAs) for marketing authorization or supplemental new drug applications (sNDAs) for extending the range of indication and/or posology, in addition to the method of administration. The PMDA is a Japanese regulatory agency sharing responsibilities with the Ministry of Health, Labour and Welfare (MHLW) of Japan. In contrast, in the European Union (EU), GCP inspections are usually requested during the initial review of a marketing authorization application (MAA), but could be requested post-authorization by the European Medicines Agency \[[@bib2]\]. These inspections may be routine or may be triggered by issues arising during the validation of the pivotal clinical trials submitted to the EMA, through assessment of the application dossier by the assessors, or through other information such as previous inspection experience \[[@bib2]\]. In the United States (US), GCP inspections are implemented by the US Food and Drug Administration (FDA) in the same manner as the EU. Watanabe et al. reported that the regulatory framework of GCP inspections in the US and EU make it possible for regulatory authorities to conduct on-going investigations of trials and also to conduct system-based investigations rather than submitted documents-based and accuracy-oriented investigations \[[@bib3]\].

The conclusions of the GCP inspection in Japan were classified into three categories as "Compliance," "Compliance with condition," and "Non-compliance." The first category means that the application dossier was acceptable, and if necessary, voluntary actions were indicated. The second means that the violation of GCP was confirmed for a portion of the subjects. Therefore, the application dossier can be accepted after excluding from the analysis the data in the NDA clinical data package for the NDAs or sNDAs. The third means that the GCP violation was found to be general and systematic. Therefore, the application dossier submitted is not reliable, and all clinical trial data should be deleted.

It is important to avoid deleting the data of subjects participating in clinical trials. To do so, it is important to understand why these data were recently eliminated from the NDAs or sNDA packages. To date, some studies have analyzed GCP deficiencies in submitted trials for NDAs or sNDAs approved by the MHLW of Japan from the 1990s to the 2000s \[[@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10]\]. A study has examined the quality in oncological clinical trials for NDA or sNDA in Japan, between April 2004 and March 2010 \[[@bib11]\], and has indicated that the exclusion of patients from the review objective due to serious violations of GCP in 40 audits for oncology drug applications was observed in 2 (5.0%) cases, whereas that in the remaining 343 audits for drug applications of the other therapeutic area was observed in 40 (11.7%) cases. However, to our knowledge, there are no recent papers examining compliance with GCP in submitted trials for NDAs or sNDAs.

In this study, we examined in detail the contents of deleted subject data in the results of GCP on-site inspections in Japan for NDAs or sNDAs between January 2007 and December 2017. As a result, we aimed to reveal the considerations in clinical trial operations related to GCP when designing, conducting, recording, and reporting the trials.

2. Methods {#sec2}
==========

We gathered review reports of NDAs or sNDAs approved in Japan between January 2007 and December 2017 from the official PMDA website. These reports contain information about PMDA\'s conclusion concerning the results of the GCP inspections. GCP on-site inspection in Japan is performed for the sponsor and clinical sites. For each NDA or sNDA, the following data were collected: the medicinal classification of the approved drug, approval year, and PMDA\'s judgment on GCP compliance.

For all, we extracted the NDAs or sNDAs for which PMDA classified into "Compliance with condition" at the conclusion of the inspections. Next, we examined the reason why PMDA made a judgment of non-compliance with GCP, and specified the responsible participants (sponsor or clinical trial site) due to deﬁciencies. We classified findings at the clinical trial site into "General findings" and "Findings for individual subjects," and examined these in detail. We also examined the relationship between approval year and findings at the clinical trial site.

3. Results {#sec3}
==========

From 2007 to 2017, 1193 NDAs or sNDAs were approved in Japan. GCP on-site inspections were conducted for 985 NDAs or sNDAs. However, inspections were not conducted for the other NDAs or sNDAs, because their data indicated that there were no clinical trials subjected to GCP on-site inspections. From the results of GCP on-site inspections in Japan, in the case of 33 NDAs or sNDAs, the subject data were removed from the submitted data due to GCP non-compliance. These results are shown in [Table 1](#tbl1){ref-type="table"}.Table 1Conclusion of GCP on-site inspections.Table 1YearNumber of approved NDAsNumber of GCP on-site inspectionsNumber of NDAs with subjects\' data deleted20078370820087965420099482102010109913201113088220121218822013125950201413211412015108101220161251100201787811Total119398533

We examined the reason why PMDA judged the 33 NDAs or sNDAs as non-compliant with GCP. Of the 33, 1 was found to be non-compliant due to the sponsor and 32 were reported at the clinical trial site. In the former, the sponsor did not appropriately perform the duties related to preparation and management of the clinical trial, and may have caused a delay in providing safety information or made a false statement in the monitoring activities. On the other hand, we examined in detail, the latter 32 NDAs or sNDAs. The results revealed that findings in the clinical site could be classified into "General findings" and "Findings for individual subjects." "General findings" were found in 6 NDAs or sNDAs and "Findings for individual subjects" in 25, while both were found in 1.

The therapeutic categories for the 33 NDAs or sNDAs are shown in [Fig. 1](#fig1){ref-type="fig"}. Central nervous system was the most popular target, followed by metabolism, oncology, and blood and body fluids.Fig. 1Therapeutic categories for the 33 NDAs or sNDAs.Fig. 1

3.1. General findings {#sec3.1}
---------------------

For 2 out of 7 NDAs or sNDAs, we found 2 findings each, and for the others, we found 1 each. Thus, for 9 findings, the details of "General findings" are shown in [Table 2](#tbl2){ref-type="table"}. Problems related to the Institutional Review Board (IRB) was the most common reason for non-compliance with GCP, followed by Investigator, and Control of Investigational Product. The details of problems related to "IRB" were that it did not maintain written records of its activities (2 NDAs), did not perform its functions according to written operating procedures, and did not been established according to the ministerial ordinance on GCP in Japan. The detail of problem related to "Investigator" was that he/she did not fulfil his/her responsibilities. The detail of problems related to "Control of Investigational Products" was that the investigator/institution did not file records of the use of investigational products by each subject.Table 2Details of general findings.Table 2ReasonNumber (Rate)IRB4 (44.4)Investigator3 (33.3)Control of Investigational Products2 (22.2)Total9 (100)

3.2. Findings for individual subjects {#sec3.2}
-------------------------------------

For 2 of 26 NDAs or sNDAs, we came up with 2 findings each, and for the rest, 1 each. Therefore, for 28 findings, the details of "Findings for individual subjects" are shown in [Table 3](#tbl3){ref-type="table"}. Record keeping was the most common reason for not including data, followed by selection of subjects, informed consent, and protocol deviations. Protocol deviations were defined as any content other than selection of subjects.Table 3Details of findings for individual subjects.Table 3ReasonNumberRate (95% confidence interval)Record keeping1760.7 (40.6, 78.5)Selection of subjects621.4 (8.3, 41.0)Informed consent310.7 (2.3, 28.2)Protocol deviations27.1 (0.9, 23.5)Total28100

The detailed contents of the 8 findings related to the selection of subjects (6 findings) and protocol deviations (2 findings) are shown in [Table 4](#tbl4){ref-type="table"}.Table 4Detailed Contents of Findings Related to Selection of Subjects and Protocol Deviations. The detailed contents of 3 findings related to informed consent are shown in [Table 5](#tbl5){ref-type="table"}.Table 4Approval dateNon-proprietary nameIndicationDetailed contentsOct. 2010Polyethylene glycol treated human normal immunoglobulinImprovement of muscle weakness in patients with chronic inflammatory demyelinating polyradiculoneuropathy (including multifocal motor neuropathy)2 patients were proven not to comply with inclusion criteria (resistant to corticosteroids) owing to inconsistency between source documents and case report forms.Oct. 2009AprepitantAcute and delayed nausea and vomiting associated with cancer chemotherapy including cisplatinOne patient met exclusion criteria.Apr. 2009Sodium-potassium formulation\
Mosapride Citrate HydrateBowel cleansing prior to barium enema X-ray examinationPrincipal investigator and 3 sub-investigators were registered as trial subjects.July 2008Mometasone furoate hydrateAllergic rhinitisFor a subject, all hematologic tests were never implemented throughout the duration of clinical trial.Oct. 2007Gadoxetate SodiumContrast of liver tumors in magnetic resonance imaging (MRI)Some patients did not meet inclusion criteria.Oct. 2007NicorandilAcute heart failureOne patient did not meet inclusion criteria (pulmonary artery wedge pressure \>13 mmHg).For a subject, an investigational drug was administrated over the defined time period. For a subject, an excessive amount of an investigational drug was administrated.Oct. 2007Glucose and inorganic salts formulationIrrigation and perfusion during surgery2 patients participated in other clinical trials of 5-ALA at the same time.Table 5Detailed contents of findings related to informed consent and protocol deviations.Table 5Approved inNon-proprietary nameIndicationDetailed contentsJune 2012AxitinibAdvanced and metastatic renal cell carcinomaConsent was not acquired again after supplying the subject with information that was relevant to the subject\'s willingness to continue participation in the trial.Oct. 2009VancomycinMRSA, MRSEAn impartial witness did not attend the informed consent process despite the subject having visual impairment.Jan. 2009Nalfurafine HydrochlorideImprovement of pruritus in hemodialysis patients (for use only when conventional treatments are not sufficiently effective)Consent had been obtained from a subject\'s legally acceptable representative but not authorized by the protocol and its details were also unknown.

3.3. Approval year and findings {#sec3.3}
-------------------------------

For 36 findings at the clinical trial site, the relationship between approval year and findings is shown in [Table 6](#tbl6){ref-type="table"}. The GCP violations were mostly found in 2007 and 2009, and few violations were found after 2013.Table 6Approval year and 36 findings.Table 620072008200920102011201220132014201520162017General findings40201200000IRB20100100000Investigator10100100000Control of investigational products10001000000Monitoring00000000000**Finding for individual subjects65831201101**Record keeping24421101101Selection of subjects30210000000Informed consent00200100000Protocol deviations11000000000**Total1051032401101**

4. Discussion {#sec4}
=============

For 33 (2.8%) out of 1193 NDAs or sNDAs approved in Japan between 2007 and 2017, there were 37 instances of GCP non-compliance findings; 1 by the sponsor and 32 at the clinical trial site. Of the 32 applications at the clinical trial site, 9 cases were categorized as "General findings" and 28 as "Findings for individual subjects." In a previous study \[[@bib9]\], there were 52 (19.8%) cases non-compliant with GCP out of 267 NDAs or sNDAs approved in Japan between April 1999 and March 2006. Therefore, though ICH-GCP were enacted in 1997, it was suggested that recent trials have become much better in quality than those conducted in the early 2000s.

Our descriptive study had certain limitations. We were not able to use the full on-site GCP inspection data, because the PMDA review reports are the only available data source and these do not contain detailed data. Cases in which pivotal trials in the NDA or sNDA package was conducted in foreign countries or multiple regions, the PMDA conducts on-site GCP inspection overseas \[[@bib12]\]. However, it was impossible to distinguish whether GCP deficiencies occurred in Japan or foreign countries, because the institution that recognized GCP deficiencies was not clarified in the PMDA review reports. However, it was possible to evaluate considerations related to the implementation of clinical trials to avoid deleting the subject data.

We examined these 28 "Findings for individual subjects" in detail. Of 17 findings related to record keeping, 15 involved loss of medical records, and 2 involved loss of source documents related to the primary endpoint. In the case of the introduction of electronic medical records by the medical institution, there is a low possibility of loss of records. However, when conducting clinical trials at a medical institution that has not introduced electronic medical records, it is necessary to be careful about maintaining the records. It is important to research how to maintain medical records and include a record preservation period when selecting medical institutions for clinical trials.

Second, we examined in depth 8 findings related to the selection of subjects (6 findings) and protocol deviations (2 findings) ([Table 4](#tbl4){ref-type="table"}). Although it was not clearly indicated, the data suggest the need for carefully ensuring that a subject satisfies the inclusion criteria for the study, which is also related to the study\'s efficacy evaluation. It is also necessary to carefully check the accuracy and completeness of subject selection during monitoring and audit.

Third, we examined in detail, 3 findings related to informed consent ([Table 6](#tbl6){ref-type="table"}). The results suggested the need to be especially careful if the subject cannot read the relevant documentation supplied (for instance, the informed consent form), or if the consent of the subject\'s legally acceptable representative is required. It is important to check whether an impartial witness or the subject\'s legally acceptable representative needs to attend the informed consent process.

As shown in [Table 6](#tbl6){ref-type="table"}, the most GCP violations were found from 2007 to 2012, and few violations were found after 2013. As a reason for this tendency, there is a possibility that the effective structure of clinical trials was gradually ensured during the 2010s because "New 5-Year Clinical Trial Activation Plan" \[[@bib13]\] was started by MHLW of Japan since April 2007.

5. Conclusion {#sec5}
=============

The results of this study reveal that record keeping was the most common reason for deleting subject data from the submitted data in the results of GCP inspections. We revealed that it is necessary to be careful about maintaining medical records, especially when conducting clinical trials at medical institutions that have not introduced electronic medical records. We indicated the need for carefully ensuring that a subject satisfies the inclusion criteria for a study, which is also related to the study\'s efficacy evaluation. We also indicated the need to be especially careful if the subject cannot read the relevant documentation supplied (for instance, the consent form), or if the consent of the subject\'s legally acceptable representative is required.

The findings of GCP inspections may be useful for identifying risks when determining an appropriate risk-based monitoring plan. The clinical development of medicines is a global undertaking. Therefore, in the future, we would like to evaluate whether there are differences in the GCP inspection conclusions between the US, EU, and Japan.

Appendix A. Supplementary data {#appsec1}
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The following is the Supplementary data to this article:Multimedia component 1Multimedia component 1

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.conctc.2019.100416>.
